Share Price and Basic Stock Data
Last Updated: December 25, 2025, 2:48 am
| PEG Ratio | -1.86 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Kopran Ltd, operating in the pharmaceuticals sector, reported a market capitalization of ₹717 Cr and a share price of ₹149. The company’s revenue from operations for the trailing twelve months (TTM) stood at ₹592 Cr, reflecting a growth trajectory from ₹551 Cr in FY 2023 to ₹630 Cr in FY 2025. Quarterly sales demonstrated fluctuations, with a peak of ₹186.08 Cr in March 2024 and a decline to ₹135.22 Cr by June 2025. The company recorded a significant annual sales increase of 8% from FY 2024 to FY 2025. The operating profit margin (OPM) has been relatively stable, reported at 10.45%, indicating effective cost management despite varying sales volumes. The revenue growth is supported by a diverse product portfolio and a strong distribution network, making Kopran a competitive player in the Indian pharmaceutical landscape.
Profitability and Efficiency Metrics
Kopran Ltd’s profitability metrics reveal a mixed performance landscape. The company recorded a net profit of ₹39 Cr for FY 2025, a decrease from ₹51 Cr in FY 2024, resulting in a net profit margin of 6.12%. The return on equity (ROE) for FY 2025 was reported at 7.43%, which is relatively low compared to industry averages, indicating potential areas for improvement. The interest coverage ratio (ICR) stood at 8.23x, reflecting a strong ability to meet interest obligations. However, the cash conversion cycle (CCC) of 170 days suggests inefficiencies in managing working capital, particularly in inventory management and receivables. The operating profit margin has shown resilience, particularly with a reported OPM of 10.45%, which can be viewed positively in light of fluctuating sales figures.
Balance Sheet Strength and Financial Ratios
Kopran Ltd demonstrates a balanced financial structure, with total borrowings of ₹157 Cr against reserves of ₹453 Cr. The debt-to-equity ratio stands at 0.28, indicating a conservative leverage position relative to its equity base. The company has reported a book value per share of ₹107.35, reflecting solid retained earnings and shareholder equity growth. The current ratio of 1.76 is favorable, suggesting adequate liquidity to meet short-term liabilities. Furthermore, the return on capital employed (ROCE) stood at 11.04%, which, while lower than previous years, still indicates effective use of capital. The enterprise value (EV) of ₹967.40 Cr, combined with an EV/EBITDA ratio of 12.58, suggests that the company is reasonably valued compared to its earnings potential, providing a stable outlook for investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Kopran Ltd highlights a diverse ownership base, with promoters holding 44.43% of the shares, while public shareholders own 54.99%. The presence of foreign institutional investors (FIIs) at 0.60% and a lack of domestic institutional investors (DIIs) indicates limited institutional interest, which could reflect cautious investor sentiment. The number of shareholders has increased to 62,222, indicating rising retail interest and potential for broader market engagement. The dividend payout ratio for FY 2025 was reported at 37.51%, which is a positive sign for income-focused investors. However, the declining trend in net profit from ₹51 Cr in FY 2024 to ₹39 Cr in FY 2025 may raise concerns among investors regarding the company’s growth trajectory and profitability sustainability.
Outlook, Risks, and Final Insight
Kopran Ltd’s outlook presents both opportunities and challenges. The company’s focus on expanding its product lines and enhancing operational efficiencies can drive future growth. However, the risks include increasing competition in the pharmaceutical sector, potential regulatory changes, and the need to improve working capital management, as indicated by the elevated cash conversion cycle. If Kopran can successfully navigate these challenges while maintaining its profitability metrics, it has the potential to enhance shareholder value. Conversely, failure to address these operational inefficiencies may hinder growth prospects and investor confidence. Overall, the company appears well-positioned to leverage its market presence but must remain vigilant in addressing its operational challenges to sustain its growth momentum.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 135 Cr. | 107 | 231/84.3 | 29.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,770 Cr. | 438 | 479/192 | 98.8 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.7 Cr. | 33.3 | 35.0/17.0 | 116 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,181.97 Cr | 1,153.40 | 53.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 125.62 | 116.97 | 158.00 | 148.88 | 117.00 | 152.59 | 158.92 | 186.08 | 139.44 | 151.56 | 166.24 | 172.36 | 135.22 |
| Expenses | 112.46 | 106.83 | 145.68 | 136.72 | 110.69 | 129.76 | 135.34 | 164.39 | 121.28 | 136.83 | 146.39 | 155.27 | 121.09 |
| Operating Profit | 13.16 | 10.14 | 12.32 | 12.16 | 6.31 | 22.83 | 23.58 | 21.69 | 18.16 | 14.73 | 19.85 | 17.09 | 14.13 |
| OPM % | 10.48% | 8.67% | 7.80% | 8.17% | 5.39% | 14.96% | 14.84% | 11.66% | 13.02% | 9.72% | 11.94% | 9.92% | 10.45% |
| Other Income | 0.65 | 0.44 | 2.22 | 3.78 | 2.39 | 0.13 | 2.43 | 9.67 | 2.63 | 1.00 | 0.17 | 3.26 | 2.56 |
| Interest | 0.79 | 1.28 | 2.24 | 1.78 | 1.83 | 1.94 | 2.24 | 2.59 | 2.18 | 2.23 | 2.16 | 2.77 | 2.54 |
| Depreciation | 3.05 | 3.25 | 3.16 | 3.24 | 3.26 | 2.77 | 3.27 | 3.59 | 3.87 | 3.85 | 4.00 | 3.87 | 4.26 |
| Profit before tax | 9.97 | 6.05 | 9.14 | 10.92 | 3.61 | 18.25 | 20.50 | 25.18 | 14.74 | 9.65 | 13.86 | 13.71 | 9.89 |
| Tax % | 23.77% | 23.14% | 23.96% | 26.37% | 22.99% | 24.55% | 23.02% | 26.01% | 24.69% | 23.42% | 24.96% | 29.39% | 24.67% |
| Net Profit | 7.60 | 4.65 | 6.95 | 8.04 | 2.77 | 13.77 | 15.79 | 18.62 | 11.10 | 7.38 | 10.40 | 9.68 | 7.45 |
| EPS in Rs | 1.58 | 0.96 | 1.44 | 1.67 | 0.57 | 2.86 | 3.28 | 3.86 | 2.30 | 1.53 | 2.16 | 2.01 | 1.54 |
Last Updated: August 1, 2025, 6:15 pm
Below is a detailed analysis of the quarterly data for Kopran Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 135.22 Cr.. The value appears to be declining and may need further review. It has decreased from 172.36 Cr. (Mar 2025) to 135.22 Cr., marking a decrease of 37.14 Cr..
- For Expenses, as of Jun 2025, the value is 121.09 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 155.27 Cr. (Mar 2025) to 121.09 Cr., marking a decrease of 34.18 Cr..
- For Operating Profit, as of Jun 2025, the value is 14.13 Cr.. The value appears to be declining and may need further review. It has decreased from 17.09 Cr. (Mar 2025) to 14.13 Cr., marking a decrease of 2.96 Cr..
- For OPM %, as of Jun 2025, the value is 10.45%. The value appears strong and on an upward trend. It has increased from 9.92% (Mar 2025) to 10.45%, marking an increase of 0.53%.
- For Other Income, as of Jun 2025, the value is 2.56 Cr.. The value appears to be declining and may need further review. It has decreased from 3.26 Cr. (Mar 2025) to 2.56 Cr., marking a decrease of 0.70 Cr..
- For Interest, as of Jun 2025, the value is 2.54 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.77 Cr. (Mar 2025) to 2.54 Cr., marking a decrease of 0.23 Cr..
- For Depreciation, as of Jun 2025, the value is 4.26 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.87 Cr. (Mar 2025) to 4.26 Cr., marking an increase of 0.39 Cr..
- For Profit before tax, as of Jun 2025, the value is 9.89 Cr.. The value appears to be declining and may need further review. It has decreased from 13.71 Cr. (Mar 2025) to 9.89 Cr., marking a decrease of 3.82 Cr..
- For Tax %, as of Jun 2025, the value is 24.67%. The value appears to be improving (decreasing) as expected. It has decreased from 29.39% (Mar 2025) to 24.67%, marking a decrease of 4.72%.
- For Net Profit, as of Jun 2025, the value is 7.45 Cr.. The value appears to be declining and may need further review. It has decreased from 9.68 Cr. (Mar 2025) to 7.45 Cr., marking a decrease of 2.23 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.54. The value appears to be declining and may need further review. It has decreased from 2.01 (Mar 2025) to 1.54, marking a decrease of 0.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:05 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 303 | 326 | 296 | 310 | 313 | 358 | 360 | 492 | 478 | 551 | 615 | 630 | 592 |
| Expenses | 260 | 294 | 266 | 274 | 283 | 312 | 313 | 410 | 390 | 499 | 540 | 557 | 546 |
| Operating Profit | 43 | 31 | 30 | 36 | 31 | 46 | 47 | 82 | 87 | 52 | 74 | 73 | 46 |
| OPM % | 14% | 10% | 10% | 12% | 10% | 13% | 13% | 17% | 18% | 9% | 12% | 12% | 8% |
| Other Income | 2 | -48 | 1 | 11 | 9 | 3 | -0 | 18 | 11 | 3 | 15 | 4 | 6 |
| Interest | 14 | 13 | 13 | 14 | 9 | 9 | 9 | 6 | 5 | 6 | 9 | 9 | 10 |
| Depreciation | 13 | 10 | 8 | 8 | 9 | 9 | 10 | 10 | 11 | 13 | 13 | 16 | 16 |
| Profit before tax | 17 | -39 | 11 | 25 | 23 | 32 | 28 | 83 | 82 | 36 | 68 | 52 | 26 |
| Tax % | 0% | 0% | 0% | 20% | 10% | 24% | 26% | 26% | 25% | 24% | 25% | 26% | |
| Net Profit | 17 | -39 | 11 | 20 | 20 | 24 | 21 | 62 | 61 | 27 | 51 | 39 | 18 |
| EPS in Rs | 4.40 | -9.52 | 2.48 | 4.60 | 4.74 | 5.55 | 4.86 | 14.24 | 12.66 | 5.65 | 10.57 | 7.99 | 3.65 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 21% | 24% | 53% | 28% | 38% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -329.41% | 128.21% | 81.82% | 0.00% | 20.00% | -12.50% | 195.24% | -1.61% | -55.74% | 88.89% | -23.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | 457.62% | -46.39% | -81.82% | 20.00% | -32.50% | 207.74% | -196.85% | -54.12% | 144.63% | -112.42% |
Kopran Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 12% |
| 3 Years: | 10% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | -14% |
| TTM: | -41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 18% |
| 3 Years: | -2% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 12% |
| 3 Years: | 8% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 9:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:32 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 41 | 43 | 43 | 43 | 43 | 43 | 43 | 48 | 48 | 48 | 48 | 48 |
| Reserves | 67 | 49 | 57 | 81 | 101 | 125 | 146 | 202 | 378 | 391 | 443 | 470 | 453 |
| Borrowings | 137 | 86 | 80 | 95 | 89 | 97 | 88 | 66 | 75 | 75 | 99 | 148 | 157 |
| Other Liabilities | 56 | 99 | 84 | 78 | 82 | 85 | 92 | 128 | 110 | 135 | 153 | 178 | 155 |
| Total Liabilities | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 | 813 |
| Fixed Assets | 105 | 102 | 101 | 104 | 104 | 113 | 111 | 112 | 151 | 165 | 182 | 208 | 235 |
| CWIP | 20 | 1 | 3 | 6 | 10 | 24 | 30 | 43 | 36 | 70 | 97 | 113 | 114 |
| Investments | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 174 | 172 | 160 | 187 | 201 | 214 | 229 | 284 | 425 | 415 | 465 | 522 | 465 |
| Total Assets | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 | 813 |
Below is a detailed analysis of the balance sheet data for Kopran Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 48.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 48.00 Cr..
- For Reserves, as of Sep 2025, the value is 453.00 Cr.. The value appears to be declining and may need further review. It has decreased from 470.00 Cr. (Mar 2025) to 453.00 Cr., marking a decrease of 17.00 Cr..
- For Borrowings, as of Sep 2025, the value is 157.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 148.00 Cr. (Mar 2025) to 157.00 Cr., marking an increase of 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 155.00 Cr.. The value appears to be improving (decreasing). It has decreased from 178.00 Cr. (Mar 2025) to 155.00 Cr., marking a decrease of 23.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 813.00 Cr.. The value appears to be improving (decreasing). It has decreased from 844.00 Cr. (Mar 2025) to 813.00 Cr., marking a decrease of 31.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 235.00 Cr.. The value appears strong and on an upward trend. It has increased from 208.00 Cr. (Mar 2025) to 235.00 Cr., marking an increase of 27.00 Cr..
- For CWIP, as of Sep 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 113.00 Cr. (Mar 2025) to 114.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 465.00 Cr.. The value appears to be declining and may need further review. It has decreased from 522.00 Cr. (Mar 2025) to 465.00 Cr., marking a decrease of 57.00 Cr..
- For Total Assets, as of Sep 2025, the value is 813.00 Cr.. The value appears to be declining and may need further review. It has decreased from 844.00 Cr. (Mar 2025) to 813.00 Cr., marking a decrease of 31.00 Cr..
Notably, the Reserves (453.00 Cr.) exceed the Borrowings (157.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -94.00 | -55.00 | -50.00 | -59.00 | -58.00 | -51.00 | -41.00 | 16.00 | 12.00 | -23.00 | -25.00 | -75.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 91 | 70 | 86 | 75 | 88 | 94 | 89 | 97 | 108 | 126 | 125 |
| Inventory Days | 103 | 78 | 119 | 122 | 138 | 129 | 154 | 121 | 202 | 133 | 126 | 153 |
| Days Payable | 69 | 119 | 115 | 95 | 118 | 90 | 95 | 104 | 84 | 89 | 103 | 108 |
| Cash Conversion Cycle | 101 | 50 | 74 | 113 | 96 | 127 | 153 | 106 | 215 | 152 | 149 | 170 |
| Working Capital Days | 45 | 9 | 34 | 43 | 60 | 70 | 79 | 81 | 158 | 139 | 131 | 113 |
| ROCE % | 14% | 14% | 14% | 19% | 14% | 16% | 14% | 30% | 21% | 8% | 14% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Healthcare Fund | 101,067 | 1.41 | 2.28 | 101,067 | 2025-04-22 17:25:28 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 251 | 0.07 | 0.01 | 251 | 2025-04-22 17:25:28 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 7.99 | 10.57 | 5.65 | 13.77 | 14.24 |
| Diluted EPS (Rs.) | 7.99 | 10.57 | 5.65 | 13.77 | 14.24 |
| Cash EPS (Rs.) | 11.21 | 13.24 | 8.29 | 14.96 | 16.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 107.35 | 101.90 | 91.11 | 88.40 | 56.65 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 107.35 | 101.90 | 91.11 | 88.40 | 56.65 |
| Revenue From Operations / Share (Rs.) | 130.39 | 127.48 | 114.29 | 99.05 | 113.71 |
| PBDIT / Share (Rs.) | 15.92 | 18.47 | 11.38 | 20.33 | 23.07 |
| PBIT / Share (Rs.) | 12.69 | 15.79 | 8.74 | 18.02 | 20.71 |
| PBT / Share (Rs.) | 10.76 | 14.01 | 7.48 | 16.96 | 19.27 |
| Net Profit / Share (Rs.) | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 |
| NP After MI And SOA / Share (Rs.) | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 |
| PBDIT Margin (%) | 12.21 | 14.48 | 9.95 | 20.52 | 20.28 |
| PBIT Margin (%) | 9.73 | 12.38 | 7.64 | 18.19 | 18.21 |
| PBT Margin (%) | 8.25 | 10.99 | 6.54 | 17.12 | 16.94 |
| Net Profit Margin (%) | 6.12 | 8.29 | 4.94 | 12.78 | 12.52 |
| NP After MI And SOA Margin (%) | 6.12 | 8.29 | 4.94 | 12.78 | 12.52 |
| Return on Networth / Equity (%) | 7.43 | 10.37 | 6.19 | 14.32 | 25.14 |
| Return on Capital Employeed (%) | 11.04 | 14.51 | 8.91 | 18.91 | 32.14 |
| Return On Assets (%) | 4.56 | 6.85 | 4.19 | 9.99 | 14.02 |
| Long Term Debt / Equity (X) | 0.03 | 0.03 | 0.04 | 0.04 | 0.08 |
| Total Debt / Equity (X) | 0.28 | 0.20 | 0.17 | 0.17 | 0.26 |
| Asset Turnover Ratio (%) | 0.79 | 0.88 | 0.87 | 0.45 | 0.64 |
| Current Ratio (X) | 1.76 | 2.08 | 2.25 | 2.74 | 1.72 |
| Quick Ratio (X) | 1.18 | 1.44 | 1.52 | 1.75 | 1.10 |
| Inventory Turnover Ratio (X) | 4.09 | 2.93 | 2.29 | 1.82 | 1.81 |
| Dividend Payout Ratio (NP) (%) | 37.51 | 28.38 | 53.10 | 10.62 | 10.53 |
| Dividend Payout Ratio (CP) (%) | 26.71 | 22.65 | 36.20 | 8.99 | 9.03 |
| Earning Retention Ratio (%) | 62.49 | 71.62 | 46.90 | 89.38 | 89.47 |
| Cash Earning Retention Ratio (%) | 73.29 | 77.35 | 63.80 | 91.01 | 90.97 |
| Interest Coverage Ratio (X) | 8.23 | 10.36 | 9.02 | 19.15 | 15.99 |
| Interest Coverage Ratio (Post Tax) (X) | 5.13 | 6.93 | 5.48 | 12.93 | 10.87 |
| Enterprise Value (Cr.) | 967.40 | 1330.79 | 595.14 | 1372.72 | 511.32 |
| EV / Net Operating Revenue (X) | 1.54 | 2.17 | 1.08 | 2.87 | 1.04 |
| EV / EBITDA (X) | 12.58 | 14.95 | 10.85 | 14.01 | 5.13 |
| MarketCap / Net Operating Revenue (X) | 1.34 | 2.03 | 0.96 | 2.84 | 0.92 |
| Retention Ratios (%) | 62.48 | 71.61 | 46.89 | 89.37 | 89.46 |
| Price / BV (X) | 1.63 | 2.54 | 1.21 | 3.19 | 1.85 |
| Price / Net Operating Revenue (X) | 1.34 | 2.03 | 0.96 | 2.84 | 0.92 |
| EarningsYield | 0.04 | 0.04 | 0.05 | 0.04 | 0.13 |
After reviewing the key financial ratios for Kopran Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.21. This value is within the healthy range. It has decreased from 13.24 (Mar 24) to 11.21, marking a decrease of 2.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 130.39. It has increased from 127.48 (Mar 24) to 130.39, marking an increase of 2.91.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.92. This value is within the healthy range. It has decreased from 18.47 (Mar 24) to 15.92, marking a decrease of 2.55.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.69. This value is within the healthy range. It has decreased from 15.79 (Mar 24) to 12.69, marking a decrease of 3.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.76. This value is within the healthy range. It has decreased from 14.01 (Mar 24) to 10.76, marking a decrease of 3.25.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
- For PBDIT Margin (%), as of Mar 25, the value is 12.21. This value is within the healthy range. It has decreased from 14.48 (Mar 24) to 12.21, marking a decrease of 2.27.
- For PBIT Margin (%), as of Mar 25, the value is 9.73. This value is below the healthy minimum of 10. It has decreased from 12.38 (Mar 24) to 9.73, marking a decrease of 2.65.
- For PBT Margin (%), as of Mar 25, the value is 8.25. This value is below the healthy minimum of 10. It has decreased from 10.99 (Mar 24) to 8.25, marking a decrease of 2.74.
- For Net Profit Margin (%), as of Mar 25, the value is 6.12. This value is within the healthy range. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.12. This value is below the healthy minimum of 8. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.43. This value is below the healthy minimum of 15. It has decreased from 10.37 (Mar 24) to 7.43, marking a decrease of 2.94.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.04. This value is within the healthy range. It has decreased from 14.51 (Mar 24) to 11.04, marking a decrease of 3.47.
- For Return On Assets (%), as of Mar 25, the value is 4.56. This value is below the healthy minimum of 5. It has decreased from 6.85 (Mar 24) to 4.56, marking a decrease of 2.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.28. This value is within the healthy range. It has increased from 0.20 (Mar 24) to 0.28, marking an increase of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.79. It has decreased from 0.88 (Mar 24) to 0.79, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.76, marking a decrease of 0.32.
- For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.18, marking a decrease of 0.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.09. This value is within the healthy range. It has increased from 2.93 (Mar 24) to 4.09, marking an increase of 1.16.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.51. This value is within the healthy range. It has increased from 28.38 (Mar 24) to 37.51, marking an increase of 9.13.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 26.71. This value is within the healthy range. It has increased from 22.65 (Mar 24) to 26.71, marking an increase of 4.06.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.49. This value is within the healthy range. It has decreased from 71.62 (Mar 24) to 62.49, marking a decrease of 9.13.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 73.29. This value exceeds the healthy maximum of 70. It has decreased from 77.35 (Mar 24) to 73.29, marking a decrease of 4.06.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.23. This value is within the healthy range. It has decreased from 10.36 (Mar 24) to 8.23, marking a decrease of 2.13.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.13. This value is within the healthy range. It has decreased from 6.93 (Mar 24) to 5.13, marking a decrease of 1.80.
- For Enterprise Value (Cr.), as of Mar 25, the value is 967.40. It has decreased from 1,330.79 (Mar 24) to 967.40, marking a decrease of 363.39.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.54. This value is within the healthy range. It has decreased from 2.17 (Mar 24) to 1.54, marking a decrease of 0.63.
- For EV / EBITDA (X), as of Mar 25, the value is 12.58. This value is within the healthy range. It has decreased from 14.95 (Mar 24) to 12.58, marking a decrease of 2.37.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
- For Retention Ratios (%), as of Mar 25, the value is 62.48. This value is within the healthy range. It has decreased from 71.61 (Mar 24) to 62.48, marking a decrease of 9.13.
- For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 1.63, marking a decrease of 0.91.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kopran Ltd:
- Net Profit Margin: 6.12%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.04% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.43% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 41 (Industry average Stock P/E: 53.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.28
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.12%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Parijat House, 1076, Dr. E. Moses Road, Mumbai Maharashtra 400018 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Susheel G Somani | Chairman |
| Mr. Surendra Somani | Executive Vice Chairman |
| Mr. Adarsh Somani | Director |
| Mr. Varun Somani | Director |
| Dr. Siddhan Subramanian | Independent Director |
| Dr. Sunita Banerji | Independent Director |
| Mrs. Mamta Biyani | Independent Director |
| Mr. Narayan Atal | Independent Director |
FAQ
What is the intrinsic value of Kopran Ltd?
Kopran Ltd's intrinsic value (as of 25 December 2025) is 265.85 which is 77.23% higher the current market price of 150.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 722 Cr. market cap, FY2025-2026 high/low of 222/123, reserves of ₹453 Cr, and liabilities of 813 Cr.
What is the Market Cap of Kopran Ltd?
The Market Cap of Kopran Ltd is 722 Cr..
What is the current Stock Price of Kopran Ltd as on 25 December 2025?
The current stock price of Kopran Ltd as on 25 December 2025 is 150.
What is the High / Low of Kopran Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kopran Ltd stocks is 222/123.
What is the Stock P/E of Kopran Ltd?
The Stock P/E of Kopran Ltd is 41.0.
What is the Book Value of Kopran Ltd?
The Book Value of Kopran Ltd is 104.
What is the Dividend Yield of Kopran Ltd?
The Dividend Yield of Kopran Ltd is 2.01 %.
What is the ROCE of Kopran Ltd?
The ROCE of Kopran Ltd is 9.75 %.
What is the ROE of Kopran Ltd?
The ROE of Kopran Ltd is 7.64 %.
What is the Face Value of Kopran Ltd?
The Face Value of Kopran Ltd is 10.0.